Back

Global Learning Collaborative

  • Castration
  • Prostatic Neoplasms

The Future of mCSPC: Molecular Profiling and Biomarker-Directed Therapies

This podcast explores the evolving role of molecular profiling and biomarker testing in metastatic castration-sensitive prostate cancer (mCSPC). Drs. Neeraj Agarwal and Rana McKay discuss the clinical significance of PTEN loss and other genomic alterations, their prognostic implications, and how they may inform treatment selection. The conversation reviews emerging data on targeted therapeutic strategies and the integration of precision medicine earlier in the disease course. Practical considerations for incorporating biomarker assessment into clinical decision-making are also examined.

Credit & MOC Details

Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.

Credit types

AAPA Category 1 Credit™Up to 0.25 creditsAMA PRA Category 1 Credit™Up to 0.25 creditsNursingUp to 0.25 creditsPharmacyUp to 0.25 credits

MOC types

No MOC

FDA REMS

No

Qualifies for MIPS

No

Pricing

Free

Reported to ACCME by the provider

  • Podcast / audio
  • Credit · Up to 0.25 credits
  • Commercial Support
  • Released
    Jun 30, 2026
  • Last day to claim credit
    Jul 1, 2027 9 months left